The expanded CMS coverage widens access to minimally invasive endovascular carotid therapy for patients with carotid artery disease. Cordis develops the Precise Pro Rx carotid stent system for this therapy. In a news release, the company shared its appreciation for physicians demonstrating the value of carotid artery stenting (CAS).
Dr. Adnan Siddiqui highlighted the “Carotid Coalition,” a group of physicians working to demonstrate the safety and efficacy of CAS. Siddiqui, professor and vice chair in the State University of Buffalo Dept. of Neurosurgery, said the multi-disciplinary approach now provides physicians and patients increased access to the therapy.
In the release, he said it enables patients and physicians to “collectively make the best decision for themselves.”
Cordis aims to continue supporting the growth of physician and patient access to CAS therapy and decrease stroke occurrence.
“Physician training is needed to increase the number of skilled interventionalists who can offer CAS to patients,” said Dr. George Adams, Cordis CMO. “Cordis will be announcing additional physician training opportunities in the coming months. Cordis is also committed to investment in carotid product innovation to continue improvement of the clinical outcomes that physicians can offer patients. We are honored to support therapy growth for a procedure that so many physicians have fought for.”